Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates oral antimicrobial agents for the treatment of non-bacteremic acute urinary tract infection caused by Extended Spectrum Beta Lactamase producing Escherichia coli or Klebsiella pneumoniae in Post-kidney transplantation. Patients are treated with intravenous (IV) antibiotics follow by oral sitafloxacin or IV ertapenem.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Khon Kaen University
• Treatments: Ertapenem; Fluoroquinolones; Sitafloxacin

Criteria

Inclusion Criteria:

• Age >18 years

• Acute urinary infection by definitions

• Positive urine culture for Extended Spectrum Beta Lactamase E. coli or K. pneumoniae ≥105 colony forming unit/mL

• Post-kidney transplantation

• Voluntarily consented to be enrolled in the study

Exclusion Criteria:

• Sepsis

• Positive blood culture

• Mixed organism of urine culture

• Immunocompromised conditions other than post-kidney transplantation

• Pregnancy or lactation

• Previous urinary tract infections within 4 weeks

• Contraindicated for fluoroquinolones and carbapenems